Soc. Generale Put 4.5 ATO 20.09.2.../ DE000SU0VT72 /
5/31/2024 10:13:14 AM | Chg.0.00 | Bid10:00:35 PM | Ask10:00:35 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
2.74EUR | 0.00% | - Bid Size: - |
- Ask Size: - |
Atos SE | 4.50 EUR | 9/20/2024 | Put |
GlobeNewswire
5/30
Groundbreaking Technology Solves Major Problem of User Lockouts During MFA Resets
GlobeNewswire
5/28
Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast...
GlobeNewswire
5/16
Nametag Enlisted by Newfold Digital in the Fight Against Fraud and Cybersecurity Threats
GlobeNewswire
5/15
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Tria...
GlobeNewswire
5/13
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
4/29
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...
GlobeNewswire
4/15
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endo...
GlobeNewswire
4/11
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
GlobeNewswire
4/9
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100%...
GlobeNewswire
4/1
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
GlobeNewswire
3/25
Nametag Launches Self-Service Account Recovery Solution That Stops AI-Generated Deepfake Attacks
GlobeNewswire
3/19
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Acce...
GlobeNewswire
3/18
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
GlobeNewswire
3/12
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Dir...
GlobeNewswire
3/6
Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Can...
GlobeNewswire
2/22
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study